spec sheet10 rows
GTX-027 is described as an experimental selective androgen receptor modulator (SARM) associated with GTx, the company behind better-known compounds of this class such as enobosarm (ostarine) and andarine. Publicly verifiable information specific to GTX-027 is extremely limited; under that designation it does not appear in the indexed biomedical literature or in clinical-trial registries. It has not been approved and is best regarded as a thinly documented research designation within the SARM class [1][2][3].
- expected anabolic effect on muscle
- possible bone support
- non-steroidal profile
Overview
Selective androgen receptor modulators, or SARMs, are a class of mostly non-steroidal compounds that bind the androgen receptor, the protein through which testosterone exerts its effects, and are designed to activate it in a tissue-selective way; the aim is to reproduce the muscle- and bone-building actions of androgens while reducing effects on tissues such as the prostate [1][2]. The company GTx was a prominent developer of SARMs, advancing agents including enobosarm (also known as ostarine or GTx-024) and andarine, some of which reached clinical trials for conditions such as cancer-related muscle wasting [2][3]. GTX-027 is presented as another compound within this general area.
Unlike GTx's flagship SARMs, GTX-027 is very poorly documented in public sources. A search of the biomedical literature indexed in PubMed and of the ClinicalTrials.gov registry does not return records specific to a compound under the name GTX-027, and no peer-reviewed studies describing its structure, potency, or selectivity are readily available [1][2]. As a consequence, statements about its particular properties cannot be independently verified, and the compound is best treated as an obscure entry in the broader SARM landscape rather than as a well-characterized agent.
Were GTX-027 to behave as a typical member of the class, it would be expected to act as a tissue-selective androgen receptor agonist, stimulating anabolic signaling in muscle and bone while limiting stimulation of the prostate and skin [1][2]. Compounds in this class have been studied for muscle wasting, osteoporosis, and, in the case of enobosarm, cancer cachexia, where a randomized controlled trial reported gains in lean body mass without the toxic effects associated with conventional androgens [3]. Like other androgen receptor agonists, such compounds are generally expected to suppress the body's own testosterone production through hormonal feedback.
No SARM had been approved for a muscle-wasting indication as of the mid-2020s, and GTX-027 in particular is not a licensed medicine and has no established human safety record [2]. Given the near-absence of specific, verifiable information, GTX-027 should be viewed with caution and understood as a research designation rather than a proven, well-studied compound.
Mechanism
GTX-027 can be discussed only at the level of the class it is said to belong to, the selective modulators, because compound-specific data are not publicly available [1][2]. SARMs work by binding the , a nuclear hormone receptor that, once activated by an androgen, relocates to the cell nucleus and regulates the expression of genes governing muscle growth, bone density, and other androgen-dependent processes [1][2].
What distinguishes a SARM from testosterone is tissue selectivity: by binding the receptor in a particular way and recruiting a distinct set of coregulatory proteins, these compounds aim to switch on anabolic programs strongly in muscle and bone while activating the receptor only weakly in tissues such as the prostate [1][2].
Most SARMs are non-steroidal, so they are not converted by aromatase or 5-alpha-reductase into or dihydrotestosterone, and, like other agonists, they are expected to suppress the body's own testosterone through feedback on the and pituitary [1][2]. For GTX-027 specifically, no measurements of receptor binding, potency, or tissue selectivity are available in the public record, so any account of its mechanism can only be inferred from the behavior of better-characterized members of the class, such as enobosarm [2][3].
receptor fingerprint
agonist
Skeletal muscleagonist
HPG axissuppresses
Prostateweak agonist
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
There is very little published safety information for this specific compound. General SARM risks apply, including testosterone suppression, lipid changes, and possible liver strain. Buying it means relying on unregulated research suppliers with unknown purity.
Subjective profileweighing the evidence above
Barely documented; best avoided simply because there's not enough to judge safety or effect.
Resources
This entry is here for reference.
Research
- 2013first citedEffects of enobosarm on muscle wasting and physical function in patients with cancer: a double-…
- 2019most recentSelective androgen receptor modulators: current knowledge and clinical applications
- 1.Development of selective androgen receptor modulators (SARMs)
- 2.Selective androgen receptor modulators: current knowledge and clinical applications
- 3.Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
3 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is there good data on GTX-027?
No, public information on this specific code number is very limited.
Who made it?
It's associated with GTx, the company behind ostarine and andarine.
Is it safe to use?
There's not enough data to say, which is exactly why it is best avoided.
Is it approved?
No, it's a research compound.
Limitations of the evidence
- Very little verifiable public data exists for this compound
- Presented as a SARM but not documented in research or trial registries
- If a SARM, expected to suppress natural testosterone, with no human safety record